Anaemia management with subcutaneous epoetin delta in patients with chronic kidney disease (predialysis, haemodialysis, peritoneal dialysis): results of an open-label, 1-year study

BACKGROUND: Anaemia is common in patients with chronic kidney disease (CKD) and can be managed by therapy with erythropoiesis-stimulating agents (ESAs). Epoetin delta (DYNEPO(®), Shire plc) is the only epoetin produced in a human cell line. The aim of this study was to demonstrate the safety and eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Frei, Ulrich, Kwan, Jonathan TC, Spinowitz, Bruce S
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2664800/
https://www.ncbi.nlm.nih.gov/pubmed/19243619
http://dx.doi.org/10.1186/1471-2369-10-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2664800/
https://www.ncbi.nlm.nih.gov/pubmed/19243619
http://dx.doi.org/10.1186/1471-2369-10-5

Ejemplares similares